Systematic Reviews: Obtaining data from randomised controlled trials: how much do we need for reliable and informative meta-analyses?

Many randomised controlled trials compare treatments that will produce only moderate differences in outcome, but these differences can be clinically important. However, they are difficult to assess reliably and require a large amount of randomised evidence. This can be achieved through large prospective randomised trials which will accrue future patients, the meta-analysis of results from randomised trials involving patients from the past, or--ideally--both. The techniques require that all possible biases are minimised, and in meta-analyses this can best be achieved by ensuring that all of the randomised evidence--both trials and participants in those trials--is included. The meta-analysis of individual patient data has been described as the gold standard for this approach. It will remove many of the problems associated with relying solely on published data and some of the problems arising from a reliance on aggregate data, and will also add to the analyses that can be performed. Such projects, however, require considerable time and effort.

[1]  P. Armitage,et al.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design. , 1976, British Journal of Cancer.

[2]  M. Pike,et al.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. , 1977, British Journal of Cancer.

[3]  REVIEW OF MORTALITY RESULTS IN RANDOMISED TRIALS IN EARLY BREAST CANCER , 1984, The Lancet.

[4]  R. Simes Publication bias: the case for an international registry of clinical trials. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  D. Alberts,et al.  Chemotherapy in advanced ovarian cancer: an overview of randomised clinical trials. Advanced Ovarian Cancer Trialists Group. , 1991, BMJ.

[6]  Early Breast Cancer Trialists' Collaborative Group Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy 133 randomised trials involving 31 000 recurrences and 24 000 deaths among 75 000 women , 1992, The Lancet.

[7]  W. Gregory,et al.  Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: an overview of published trials. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  M. Parmar,et al.  Meta-analysis of the literature or of individual patient data: is there a difference? , 1993, The Lancet.

[9]  I. Chalmers The Cochrane Collaboration: Preparing, Maintaining, and Disseminating Systematic Reviews of the Effects of Health Care , 1993, Annals of the New York Academy of Sciences.

[10]  M. Hanna,et al.  Adjuvant active specific immunotherapy for human colorectal cancer: 6.5-year median follow-up of a phase III prospectively randomized trial. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  R. Peto,et al.  Large‐Scale Randomized Evidence: Large, Simple Trials and Overviews of Trials , 1993, Journal of clinical epidemiology.

[12]  D. Rennie,et al.  The Cochrane Collaboration. Preparing, maintaining, and disseminating systematic reviews of the effects of health care. , 1995, JAMA.